Merck & Co., Inc. (NYSE:MRK) Stock Holdings Lifted by Cullen Investment Group LTD.

Cullen Investment Group LTD. increased its holdings in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 3.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,190 shares of the company’s stock after buying an additional 2,645 shares during the period. Merck & Co., Inc. comprises approximately 1.9% of Cullen Investment Group LTD.’s investment portfolio, making the stock its 8th largest holding. Cullen Investment Group LTD.’s holdings in Merck & Co., Inc. were worth $12,017,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. NTV Asset Management LLC lifted its position in shares of Merck & Co., Inc. by 0.3% during the 4th quarter. NTV Asset Management LLC now owns 26,534 shares of the company’s stock valued at $2,893,000 after buying an additional 80 shares in the last quarter. SRS Capital Advisors Inc. raised its stake in Merck & Co., Inc. by 1.6% in the 4th quarter. SRS Capital Advisors Inc. now owns 5,037 shares of the company’s stock valued at $549,000 after purchasing an additional 81 shares during the last quarter. Endowment Wealth Management Inc. lifted its holdings in Merck & Co., Inc. by 3.2% in the 4th quarter. Endowment Wealth Management Inc. now owns 2,637 shares of the company’s stock valued at $288,000 after purchasing an additional 81 shares in the last quarter. Onyx Bridge Wealth Group LLC lifted its holdings in Merck & Co., Inc. by 0.4% in the 4th quarter. Onyx Bridge Wealth Group LLC now owns 19,166 shares of the company’s stock valued at $2,089,000 after purchasing an additional 83 shares in the last quarter. Finally, Pinnacle Holdings LLC lifted its holdings in Merck & Co., Inc. by 0.7% in the 4th quarter. Pinnacle Holdings LLC now owns 12,229 shares of the company’s stock valued at $1,333,000 after purchasing an additional 84 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analysts Set New Price Targets

MRK has been the topic of a number of research reports. Truist Financial raised their price objective on Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a report on Friday, April 26th. Argus upgraded Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price objective on shares of Merck & Co., Inc. in a report on Tuesday. Berenberg Bank raised their price objective on Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a report on Monday, April 8th. Finally, Wells Fargo & Company raised their price objective on Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a report on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average price target of $133.00.

Get Our Latest Stock Report on MRK

Merck & Co., Inc. Stock Up 0.4 %

NYSE MRK opened at $127.99 on Wednesday. Merck & Co., Inc. has a 52 week low of $99.14 and a 52 week high of $133.10. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77. The business’s fifty day simple moving average is $128.66 and its 200-day simple moving average is $122.99. The firm has a market cap of $324.17 billion, a PE ratio of 142.21, a P/E/G ratio of 2.46 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its quarterly earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.94 by $0.13. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.21 billion. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.40 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 8.64 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 8th. Investors of record on Monday, June 17th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Monday, June 17th. This represents a $3.08 annualized dividend and a yield of 2.41%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 342.22%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.